Literature DB >> 6848143

Passive participation of fixed platelets in aggregation facilitated by covalently bound fibrinogen.

G Agam, A Livne.   

Abstract

The role of fibrinogen in interplatelet recognition during aggregation was examined by combining two cell types: fresh platelets (in limiting density) activated by thrombin or A23187, and formaldehyde-fixed platelets, bearing cross-linked fibrinogen. The fixed platelets did not aggregate by themselves, nor with resting platelets, but were capable of interacting with activated platelets and of participating passively in aggregation. The participation, expressed by enhanced aggregation, was assayed by the conventional turbidometric traces and by cosedimentation of fixed 3H-platelets with aggregates of fresh platelets. Platelet suspensions, prepared without special means to avert spontaneous activation, retained plasma fibrinogen to the extent of 50 micrograms/ml of a suspension containing 10(8) platelets, and the derived fixed platelets participated in aggregation, independently of added fibrinogen. The capability of such fixed platelets to participate in aggregation was sensitive to proteolytic digestion and to massive acetylation. When platelet separation was aided by apyrase or aspirin, PGE1 and gel filtration, the residual plasma fibrinogen was limited to 0.4 micrograms/ml of 10(8) platelet suspension. The derived fixed platelets were incapable of participating in aggregation unless fibrinogen was added prior to fixation. The affixed fibrinogen could not be replaced by soluble fibrinogen or affixed albumin. It is concluded that fibrinogen, which binds to platelets upon activation or is linked to them covalently, is a recognition site for platelet-platelet interaction during aggregation.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6848143

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

Review 1.  Bio-inspired nanomedicine strategies for artificial blood components.

Authors:  Anirban Sen Gupta
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2017-03-15

Review 2.  Synthetic Strategies for Engineering Intravenous Hemostats.

Authors:  Leslie W Chan; Nathan J White; Suzie H Pun
Journal:  Bioconjug Chem       Date:  2015-04-06       Impact factor: 4.774

3.  Identification of different proaggregatory abilities of activated platelet subpopulations.

Authors:  Alena O Yakimenko; Faina Y Verholomova; Yana N Kotova; Fazoil I Ataullakhanov; Mikhail A Panteleev
Journal:  Biophys J       Date:  2012-05-15       Impact factor: 4.033

Review 4.  Bioinspired artificial platelets: past, present and future.

Authors:  Norman F Luc; Nathan Rohner; Aditya Girish; Ujjal Didar Singh Sekhon; Matthew D Neal; Anirban Sen Gupta
Journal:  Platelets       Date:  2021-08-30       Impact factor: 3.862

5.  Thromboerythrocytes. In vitro studies of a potential autologous, semi-artificial alternative to platelet transfusions.

Authors:  B S Coller; K T Springer; J H Beer; N Mohandas; L E Scudder; K J Norton; S M West
Journal:  J Clin Invest       Date:  1992-02       Impact factor: 14.808

Review 6.  Platelet-inspired nanomedicine in hemostasis thrombosis and thromboinflammation.

Authors:  Shruti Raghunathan; Julie Rayes; Anirban Sen Gupta
Journal:  J Thromb Haemost       Date:  2022-04-26       Impact factor: 16.036

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.